Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502external-prioritypatent/US4959457A/en
Priority claimed from DK241385Aexternal-prioritypatent/DK171531B1/en
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of DK56995ApublicationCriticalpatent/DK56995A/en
Application grantedgrantedCritical
Publication of DK172382B1publicationCriticalpatent/DK172382B1/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Biologically active lymphotoxin variants are synthesized in recombinant cell culture. Previously unknown nucleic acids and vectors, which have incorporated these nucleic acids, are provided. The compositions and processes which are specified make it possible to economically produce preparations which comprise homogeneous lymphotoxin variants which possess amino acid sequences which differ from those of the lymphotoxins which are found in nature by one or more amino acid residues having been (a) deleted or (b) replaced with another residue, or (c) by one or more other amino acid residues having been inserted.
Isolated biologically active human lymphotoxin derivative and antibody neutralizing its cytolytic activity, nucleic acid encoding the lymphotoxin derivative, replicable vector comprising the nucleic acid, heterologous cell transformed with the nucleic acid, and method comprising preparing the lymphotoxin derivative.
"PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION".
Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it